View More Recent Stories

Aug 31, 2022 07:30AM Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody
Aug 23, 2022 07:30AM Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
Aug 9, 2022 07:30AM Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Jun 1, 2022 07:30AM Sensei Biotherapeutics (SNSE) Appoints Patrick Gallagher as Chief Business Officer
Jun 1, 2022 07:30AM Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
May 25, 2022 07:30AM Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
May 10, 2022 07:30AM Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
Mar 10, 2022 07:30AM Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
Mar 9, 2022 04:06PM Sensei Biotherapeutics (SNSE) Appoints William Ringo as Board Chair
Mar 9, 2022 04:05PM Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
Mar 3, 2022 07:30AM Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
Feb 11, 2022 07:30AM Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit
Jan 6, 2022 08:00AM Sensei Biotherapeutics Announces Executive Promotions
Dec 16, 2021 09:01AM Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award
Dec 13, 2021 04:01PM Sensei Biotherapeutics (SNSE) Announces Addition to the Nasdaq Biotechnology Index
Dec 13, 2021 04:01PM Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
Nov 19, 2021 04:02PM Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Nov 12, 2021 07:04AM Sensei Biotherapeutics (SNSE) Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at SITC
Nov 12, 2021 07:02AM Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Nov 9, 2021 08:54AM Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
Nov 3, 2021 09:01AM Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
Oct 1, 2021 08:05AM Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Aug 4, 2021 07:45AM Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
Aug 2, 2021 08:01AM Sensei Biotherapeutics (SNSE) Appoints Kristian Humer to its Board
Aug 2, 2021 08:01AM Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
Aug 2, 2021 08:01AM Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
Jun 28, 2021 04:11PM Sensei Biotherapeutics (SNSE) Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
Jun 28, 2021 04:05PM Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
May 19, 2021 05:04PM Sensei Biotherapeutics (SNSE) Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
May 19, 2021 05:03PM Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
May 12, 2021 07:41AM Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
May 5, 2021 08:05AM Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
Apr 5, 2021 08:00AM Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors
View More Recent Stories